
|Videos|October 11, 2016
Weighing Quality of Life Improvements in Atopic Dermatitis
Advertisement
Panelists Peter L. Salgo, MD; Ed Pezalla, MD, MPH; Jeffrey D. Dunn, PharmD, MBA; and Cheryl Allen, BS Pharm, MBA, highlight the triggers to seek clinical care and the direct and indirect costs associated with the disease.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
New Data Show Elinzanetant Is a Safe, Well-Tolerated Non-Hormonal Therapy for Menopausal Vasomotor Symptoms
5















































































































































































































